---
title: "Rani Therapeutics 2025 10-K: $1.63M revenue, $(0.45) EPS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280686611.md"
description: "Rani Therapeutics reported a contract revenue of $1.633 million for the fiscal year, with a net loss per Class A share of $(0.45), totaling a net loss of $(40.95) million. Operating loss improved to $(38.31) million year-over-year. The company has $49.709 million in cash and equivalents, expected to last at least 12 months. Revenue growth was driven by collaborations, including a $10 million upfront from Chugai. The company advanced its RaniPill platform and is pursuing partnerships for commercialization while managing costs effectively."
datetime: "2026-03-26T20:45:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280686611.md)
  - [en](https://longbridge.com/en/news/280686611.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280686611.md)
generator: "portal-rs"
---

# Rani Therapeutics 2025 10-K: $1.63M revenue, $(0.45) EPS

Rani Therapeutics reported contract revenue of $1.633 million for the fiscal year and a net loss per Class A share of $(0.45), reflecting a net loss of $(40.95) million as shown in the consolidated statements. Operating loss improved to $(38.31) million year‑over‑year, while cash, cash equivalents and marketable securities totaled $49.709 million—management expects this funding to cover at least the next 12 months.

**Financial Highlights**

-   **Revenue:** Contract revenue of $1.633 million, up 58.9% versus 2024.
-   **Operating income (loss):** Loss from operations of $(38.310) million, improved 28.1% versus 2024.
-   **Net income (loss):** Net loss of $(40.950) million, a 27.6% improvement versus 2024.
-   **Net income per Class A common share:** $(0.45); weighted-average Class A shares: 66.138 million.
-   **Cash position:** Cash, cash equivalents and marketable securities of $49.709 million; management expects funding for at least 12 months.

**Business Highlights**

-   **Revenue drivers & partnerships:** Revenue increase was driven by collaboration activity, including a $10 million upfront from Chugai and related evaluation services.
-   **Product development:** Advanced the RaniPill platform—completed three Phase 1 trials for RaniPill GO and initiated a Phase 1 trial for RaniPill HC (RT-114) in December 2025.
-   **Manufacturing and operations:** Continued vertical integration with in‑house design and prototyping and investments in automated production lines to enable scale and protect intellectual property.
-   **Cost management and R&D focus:** Year‑over‑year declines in R&D and G&A due to cost containment and pausing or terminating certain programs; R&D spending is expected to increase as development programs resume.
-   **Commercial strategy:** Pursuing partnerships for development and commercialization (notably with Chugai) while retaining the option to build commercial infrastructure if products receive approval.

Original SEC Filing: Rani Therapeutics Holdings, Inc. \[ RANI \] - 10-K - Mar. 26, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [RANI.US](https://longbridge.com/en/quote/RANI.US.md)
- [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline](https://longbridge.com/en/news/296030806.md)
- [Chugai licenses anti-dengue antibody AID351 to GSK in exclusive deal](https://longbridge.com/en/news/296167792.md)
- [Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatment](https://longbridge.com/en/news/295890880.md)
- [Rani Therapeutics to present at Canaccord Genuity Annual Growth Conference](https://longbridge.com/en/news/295403455.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**